AMAGINE-2 and AMAGINE-3 are in two phase 3 studies that compare multiple doses of brodalumab (anti-IL-17) and ustekinumab (anti-12/23) in adults with moderate-to-severe psoriasis.
All News
Biologic and new drug development seldom targets children and adolescents. This study evaluated the efficacy and safety of ustekinumab in adolescents age 12 to 17 years with moderate-to-severe psoriasis,
Mease and colleagues have published their results of a phase 3 trial of secukinumab (anti-IL-17A Mab) in 606 patients with psoriatic arthritis (PsA).
Tight control in rheumatoid arthritis was introduced with the TICORA trial and validated in numerous treat-to-target studies since. Now the benefits of tight control in psoriatic arthritis (PsA) have been reported.
The ACR and SPARTAN (Spondyloarthritis Research and Treatment Network) has worked together to study 57 specific treatment questions regarding AS and SpA. The following guidelines have recently been published after conducting systematic literature reviews.
Biologics have been a great advance in therapeutics, but at great cost. Although biologics account for less than 1% of all prescriptions in the USA, they account for 28% percent of the cost of prescribed medications.
Biosimilars are rapidly growing. Many of these will have their first introduction to countries outside of the USA. There is concern whether biosimilars will provide identical pharmacodynamics, biological function, efficacy and toxicity to reference products, both in the short and long term.
Secukinumab (Cosentyx) is an anti-IL-17 monoclonal antibody currently approved for use in moderate to severe psoriasis. It has also been studied in psoriatic arthritis (PsA) and shown to be safe and effective.
Axial SpA (axSpA) is a chronic inflammatory disease that includes AS and non-radiographic axSpA (nr-axSpA).
The rheumatology therapeutic landscape has changed almost yearly in the last 15 years, with the introduction of at least 16 biologic or novel agents for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), spondyloarthritis (SpA), juvenile arthritis,
A nationwide study of 8600 ankylosing spondylitis (AS) patients from Sweden, compared survival to 40,460 controls between 2006-2012.
Valeant Acquires Brodalumab from Astra-Zeneca
Reuters reports that Valeant Pharmaceuticals International Inc (a Canadian Pharmaceutical company) is buying rights to AstraZeneca's late-stage experimental psoriasis drug, brodalumab, after it was dropped by codeveloper Amgen Inc in May. Amgen pulled out of the project b
Uveitis is a common association of juvenile idiopathic arthritis (JIA) that has previously been characterized by poor visual prognosis with limited options for effective treatment.
Haroon et al has analyzed administrative claims data from Ontario, Canada and compared 21473 AS patients with 86606 normal comparators matched for age, sex, and location of residence.
The CLEAR study was a one-year, randomized, double-blind trial compared subcutaneous standard doses of secukinumab (anti-IL17) and ustekinumab (anti-IL12/23) in patients with moderate-severe plaque psoriasis.
Musculoskeletal ultrasound (US) was recently used in a longitudinal study Achilles enthesis of 146 patients with early spondyloarthritis (SpA). Usual measures of SpA activity included BASFI, BASRI-spine, BASDAI and Ankylosing Spondylitis Disease Activity Score (ASDAS).
A recent study published in the journal Patient Preference and Adherence examined insured patients from the Optum Research Database who had moderate to severe plaque psoriasis and queried them about their satisfaction with therapy.
Methotrexate was first introduced in 1955 for leukemia and in 1986 became FDA approved for the treatment of adults with severe, active, rheumatoid arthritis or children with active polyarticular-course juvenile RA.
The British Journal of Dermatology has published online the results of an International Psoriasis Council (IPC) survey identifying 21 psoriasis research priorities. The results will also appear in a future print edition of the journal.
Wang and coworkers from the Rochester Epidemiology Project presented their findings at the annual Spondyloarthritis Research and Treatment Network.(SPARTAN) in Denver, CO.
